- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Professor: Lower Cost-Sharing for Chronic Conditions
Chronically ill patients, who are more likely to require necessary care, should pay less for health insurance, Aaron E. Carroll, a professor of pediatrics at Indiana University School of Medicine, argued in an op-ed for the New York Times.
Chronically ill patients, who are more likely to require necessary care, should pay less for health insurance, Aaron E. Carroll, a professor of pediatrics at Indiana University School of Medicine, argued in an op-ed for the New York Times.
The U.S. healthcare system should not apply cost-sharing to all insurance beneficiaries equally, said Carroll, who pointed to a recent JAMA Pediatrics study that found high cost-sharing led children with a manageable chronic condition (asthma) to delay or even skip recommended care.
"We want them to use the healthcare system. With respect to asthma, prevention and maintenance are far better than trying to treat a child already suffering from an attack," he wrote.
Read the full story here: http://bit.ly/Tvmp9R
Source: Fierce Health Payer
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More
